Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme

Abstract The approvals of nintedanib and pirfenidone changed the treatment paradigm in idiopathic pulmonary fibrosis (IPF), and increased our understanding of the underlying disease mechanisms. Nonetheless, many challenges and unmet needs remain in the management of patients with IPF and other progr...

Full description

Bibliographic Details

Published in:	Respiratory Research
Main Authors:	Claudia Valenzuela, Sebastiano Emanuele Torrisi, Nicolas Kahn, Manuel Quaresma, Susanne Stowasser, Michael Kreuter
Format:	Article
Language:	English
Published:	BMC 2020-01-01
Subjects:	nintedanib idiopathic pulmonary fibrosis literature review challenges
Online Access:	https://doi.org/10.1186/s12931-019-1269-6